Country for PR: China
Contributor: Xinhua News Agency
Wednesday, October 20 2021 - 18:51
"Developing Biomedicine in the Greater Bay Area: Opportunities and Challenges" Summit Held in Shenzhen
SHENZHEN, China, Oct. 20, 2021 /Xinhua-AsiaNet/--

On October 16, a summit titled "Developing Biomedicine in the Greater Bay Area: 
Opportunities and Challenges" was successfully held in Shenzhen, China. Top 
leaders and experts from the government, industry, academia and medical 
services gathered to explore opportunities and challenges of developing the 
biomedical industry in the Guangdong-Hong Kong-Macao Greater Bay Area under the 
current economic and international climate. 

This Summit was organized by the Office of National Brand Project of Xinhua 
News Agency, co-organized by China News Development Shenzhen, and 
Cheerland Biologics, sponsored by Shenzhen Investment Holdings Capital, with 
support from Shenzhen Dapeng New District Management Committee. 

Mr. Li Bin, Deputy Director of National Health Commission (NHC) and a member of 
the Managing Party Council of NHC, headlined the delegate of government 
officials attending the Summit. Mr. Li applauded the Centralized Volume-based 
Procurement of Drug Consumables, a major policy of the CPC Central Committee's 
drug reform efforts starting from 2020. Thanks to this new policy, China's new 
drug R&D and innovation capability, as well as quality assurance, supply 
capacity and clinical use have all been remarkably improved. 

Mr. Gong Xixiang, a member of the Managing Party Council and Secretary General 
of Xinhua News Agency, pointed out that Shenzhen, as one of the core engine 
cities in the Guangdong-Hong Kong-Macao Greater Bay Area, has aspired to become 
a leader and innovation hub for biomedicine. 

Mr. Xu Jianping, Director of the Regional Opening Department of the National 
Development and Reform Commission, urged the Greater Bay Area to play a leading 
role in developing the Health Silk Road, for the benefit of China and other 
countries involved. 

Mr. Liu Ruyin, Founder and Chairman of Cheerland Biologics, expressed that 
Cheerland, headquartered in Shenzhen, has been striving to become a regional 
and national leader in biotechnology. It has built a world-class management 
team with international executives, led by Mr. Michael Garvey, President and 
Managing Director of the Board. Cheerland also established a biomedicine 
eco-system consisted of diagnostic labs based on gene sequencing, a drug 
development platform and pipelines, medical services, and now CDMO (contract 
development and manufacturing organization). Cheerland is building the first 
large-scale biologics CDMO (Bio-CDMO) base in China, aiming to provide 
international standard, low cost, commercial scale Bio-CDMO services to global 
biotech clients. The global launch ceremony of Cheerland Bio-CDMO, and a 
service contract signing ceremony were held at the Summit.

A panel featuring academicians and industry leaders discussed how the Greater 
Bay Area can promote high-quality development of the biomedical industry under 
the current economic and geopolitical climate.  

About Cheerland Biologics

Cheerland Biologics, a co-organizer of the Summit, was established in Shenzhen 
in April 2016 and elected into the National Brand Project of Xinhua News Agency 
in April 2021. Cheerland aims to lower significantly the cost of biologics and 
make biomedicine accessible to everyone, through technological innovation and 
providing large-scale manufacturing services to the global biotech industry.

Source: Cheerland Biologics

Image Attachments Links:


   Caption: Global Launch Ceremony of Cheerland Bio-CDMO